International Consensus on Use of Continuous Glucose Monitoring

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2017 Nov 23

PMID 29162583

Citations 715

Authors

Thomas Danne

Revital Nimri

Tadej Battelino

Richard M Bergenstal

Kelly L Close

J Hans DeVries

Satish Garg

Lutz Heinemann

Irl Hirsch

Stephanie A Amiel

Roy Beck

Emanuele Bosi

Bruce Buckingham

Claudio Cobelli

Eyal Dassau

Francis J Doyle 3rd

Simon Heller

Roman Hovorka

Weiping Jia

Tim Jones

Olga Kordonouri

Boris Kovatchev

Aaron Kowalski

Lori Laffel

David Maahs

Helen R Murphy

Kirsten Norgaard

Christopher G Parkin

Eric Renard

Banshi Saboo

Mauro Scharf

William V Tamborlane

Stuart A Weinzimer

Moshe Phillip

Affiliations

Soon will be listed here.

Abstract

Measurement of glycated hemoglobin (HbA) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.

Citing Articles

Classifying Continuous Glucose Monitoring Documents From Electronic Health Records.

Zheng Y, Iturrate E, Li L, Wu B, Small W, Zweig S J Diabetes Sci Technol. 2025; :19322968251324535.

PMID: 40071848 PMC: 11904921. DOI: 10.1177/19322968251324535.

Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)-Special Interest Group in Diabetes.

Boccardi V, Bahat G, Balci C, Bourdel-Marchasson I, Christiaens A, Donini L Eur Geriatr Med. 2025; .

PMID: 40014274 DOI: 10.1007/s41999-025-01168-1.

Toward Detection of Nocturnal Hypoglycemia in People With Diabetes Using Consumer-Grade Smartwatches and a Machine Learning Approach.

Mendez C, Kaykayoglu C, Bahler T, Kunzler J, Lizoain A, Rothenbuhler M J Diabetes Sci Technol. 2025; :19322968251319800.

PMID: 39996274 PMC: 11851596. DOI: 10.1177/19322968251319800.

Availability of Open Dynamic Glycemic Data in the Field of Diabetes Research: A Scoping Review.

Del Giudice L, Piersanti A, Gobl C, Burattini L, Tura A, Morettini M J Diabetes Sci Technol. 2025; :19322968251316896.

PMID: 39953711 PMC: 11830157. DOI: 10.1177/19322968251316896.

Association between the GMI/HbA1c ratio and preclinical carotid atherosclerosis in type 1 diabetes: impact of the fast-glycator phenotype across age groups.

Puig-Jove C, Vinals C, Conget I, Quiros C, Vinagre I, Berrocal B Cardiovasc Diabetol. 2025; 24(1):75.

PMID: 39953520 PMC: 11829493. DOI: 10.1186/s12933-025-02637-4.

References

New J, Ajjan R, Pfeiffer A, Freckmann G . Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). Diabet Med. 2015; 32(5):609-17. DOI: 10.1111/dme.12713. View

Campbell M, Schatz D, Chen V, Wong J, Steck A, Tamborlane W . A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience. Pediatr Diabetes. 2013; 15(2):110-7. PMC: 4164957. DOI: 10.1111/pedi.12067. View

Cryer P . The barrier of hypoglycemia in diabetes. Diabetes. 2008; 57(12):3169-76. PMC: 2584119. DOI: 10.2337/db08-1084. View

Esposito K, Giugliano D, Nappo F, Marfella R . Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004; 110(2):214-9. DOI: 10.1161/01.CIR.0000134501.57864.66. View

Shipman K, Jawad M, Sullivan K, Ford C, Gama R . Ethnic/racial determinants of glycemic markers in a UK sample. Acta Diabetol. 2015; 52(4):687-92. DOI: 10.1007/s00592-014-0703-y. View

Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A . Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014; (2):CD009122. PMC: 6486147. DOI: 10.1002/14651858.CD009122.pub2. View

Ford E, Cowie C, Li C, Handelsman Y, Bloomgarden Z . Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2010; 3(1):67-73. DOI: 10.1111/j.1753-0407.2010.00100.x. View

. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care. 2009; 33(1):17-22. PMC: 2797966. DOI: 10.2337/dc09-1502. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

10.

Vigersky R, Fonda S, Chellappa M, Walker M, Ehrhardt N . Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2011; 35(1):32-8. PMC: 3241321. DOI: 10.2337/dc11-1438. View

11.

Weinstock R, Xing D, Maahs D, Michels A, Rickels M, Peters A . Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab. 2013; 98(8):3411-9. DOI: 10.1210/jc.2013-1589. View

12.

Bergenstal R, Gal R, Connor C, Gubitosi-Klug R, Kruger D, Olson B . Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels. Ann Intern Med. 2017; 167(2):95-102. DOI: 10.7326/M16-2596. View

13.

Lipska K, Warton E, Huang E, Moffet H, Inzucchi S, Krumholz H . HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013; 36(11):3535-42. PMC: 3816866. DOI: 10.2337/dc13-0610. View

14.

Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M . CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016; 22(1):84-113. DOI: 10.4158/EP151126.CS. View

15.

Oz G, Kumar A, Rao J, Kodl C, Chow L, Eberly L . Human brain glycogen metabolism during and after hypoglycemia. Diabetes. 2009; 58(9):1978-85. PMC: 2731528. DOI: 10.2337/db09-0226. View

16.

Heller S, Cryer P . Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991; 40(2):223-6. DOI: 10.2337/diab.40.2.223. View

17.

Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R . The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012; 55(12):3155-62. PMC: 3483098. DOI: 10.1007/s00125-012-2708-9. View

18.

McQueen R, Ellis S, Campbell J, Nair K, Sullivan P . Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes. Cost Eff Resour Alloc. 2011; 9:13. PMC: 3180394. DOI: 10.1186/1478-7547-9-13. View

19.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R . Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016; 388(10057):2254-2263. DOI: 10.1016/S0140-6736(16)31535-5. View

20.

Ly T, Brnabic A, Eggleston A, Kolivos A, McBride M, Schrover R . A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health. 2014; 17(5):561-9. DOI: 10.1016/j.jval.2014.05.008. View